RE: A BioNtech4 Apr 2019 19:01
Good find crumbs, and that missing piece from the chart............................
Partner Project(s) Financial details Date
Sanofi mRNA-based cancer therapy encoding unnamed cytokines €80m ($91m) equity investment Jan 2019
Pfizer mRNA-based influenza vaccines $120m up front, equity, "near-term" funding; $305m milestones Aug 2018
Genevant Sciences Five mRNA therapies for rare diseases 50/50 cost/profit share Jul 2018
Scancell T-cell receptor therapies for cancer None given Jan 2018
Roche mRNA-based, individualised cancer vaccines $310m up front and milestone payments Sep 2016
As we have said on many occasions, the financial details are what we are waiting for, which makes redundant a lot of the talk we know is posted to try and convince us we have troubles with funding, over and above their AGM statements that we have funding in to 2020, and as i say the whole issue is very premature given the time we have to finalise deals in many pipelines.
Who would have thought we would be seen amongst the respected companies BioNTech have agreements in place with.
Holbrook, you asked a good question earlier, was hard to respond at the time as there were too many conversations taking place, information like this, and from what you know should answer your question. Do we ever see VAL mentioned amongst such companies??
I don"t want to knock the subject matter being discused, but i do agree with rattys observation of where it will lead to, and would ask Aimbig whether he feels collaborations of these magnitudes will allay the fears that have been dredged up.??
Too many positives to ignore, which two certain posters have, I just wonder what they are both trying to achieve, and from past experience Aimbig you are going the same way, slowly demeaning every poster that has sussed you out. Fortunately there are too many of us a few steps ahead of you still.
Have a goodnight guys, a few things i wanted to mention, but can wait till tomorrow, and well done crumbs, notably for keeping it simple, it is. Goodnight.